 |
|
|
|
|
|
Treatment |
|
Location |
|
Last Updated |
|
|
|
Details |
|
A Phase II Study of Bevacizumab (Avastin) Plus Temodar and Tarceva After Radiation Therapy and Temodar in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Who Are Stable Following Radiation |
|
San Francisco, CA USA |
|
04/27/2008 |
|
|
|
|
|
Details |
|
Phase I/II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme |
|
Houston , TX |
|
04/27/2008 |
|
|
|
Details |
|
A Phase II Trial of Concurrent Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme |
|
Fort Myers, FL USA |
|
04/27/2008 |
|
|
|
|
|
Details |
|
Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme |
|
Durham, NC USA |
|
04/27/2008 |
|
|
|
Details |
|
Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme |
|
Charlottesville, VA USA |
|
04/27/2008 |
|
|
|
|
|
Details |
|
Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme |
|
New York, NY USA |
|
04/27/2008 |
|
|
|
Details |
|
Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme |
|
Boston, MA USA |
|
04/27/2008 |
|
|
|
|
|
Details |
|
A Phase II Trial of Thalidomide in combination with Temozolomide or CPT-11 in patients with recurrent anaplastic gliomas or glioblastoma multiforme
|
|
Houston, TX USA |
|
04/16/2008 |
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Pittsburgh, PA USA |
|
04/16/2008 |
|
|
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Chicago, IL USA |
|
04/16/2008 |
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Manhasset, NY USA |
|
04/16/2008 |
|
|
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
New York, NY USA |
|
04/16/2008 |
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Cleveland, OH USA |
|
04/16/2008 |
|
|
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Edison, NJ USA |
|
04/16/2008 |
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Charlottesville, VA USA |
|
04/16/2008 |
|
|
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
NEW YORK CITY, NY USA |
|
04/16/2008 |
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Chicago, IL |
|
04/16/2008 |
|
|
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Evanston, IL USA |
|
04/16/2008 |
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Zürich , Switzerland |
|
04/16/2008 |
|
|
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Lausanne, Switzerland |
|
04/16/2008 |
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
New York, NY USA |
|
04/16/2008 |
|
|
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Milwaukee, WI USA |
|
04/16/2008 |
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Cleveland, OH USA |
|
04/16/2008 |
|
|
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Innsbruck, Austria |
|
04/16/2008 |
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Prague, Czech Republic |
|
04/16/2008 |
|
|
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Augsburg, Germany |
|
04/16/2008 |
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Bridgeport, CT USA |
|
04/16/2008 |
|
|
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Boston, MA USA |
|
04/16/2008 |
|
|
|
Details |
|
Effect of NovoTTF-100A in Recurrent GBM |
|
Burlington, MA USA |
|
04/16/2008 |
|
|
|
|
|
Details |
|
Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma |
|
Durham, NC USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma |
|
Los Angeles, CA USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma |
|
San Francisco, CA USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma |
|
New York, NY USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma |
|
San Antonio, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma |
|
Bethesda, MD USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma |
|
Madison, WI USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma |
|
Pittsburgh, PA USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Durham, NC USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Los Angeles, CA USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
New York, NY USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
San Antonio, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Bethesda, MD USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Madison, WI USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Pittsburgh, PA USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Boston, MA USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I / II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Carboplatin in Adults with Recurrent Glioblastoma Multiforme
|
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Chicago, IL USA |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Phoenix, AZ USA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Detroit, MI USA |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Boston, MA USA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Winston-Salem, NC USA |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Columbus, OH USA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Halifax, Nova Scotia, Canada |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Edison, NJ USA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Orlando, FL USA |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Jacksonville, FL USA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Memphis, TN USA |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Buffalo, NY USA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
La Jolla, CA USA |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Columbus, OH USA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Evanston, IL USA |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Sacramento, CA USA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Palo Alto, CA USA |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Englewood, CO USA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Aurora, CO USA |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Portland, OR USA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Seattle, WA USA |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Madison, WI USA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Edmonton, Alberta, CANADA |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Winnipeg, Manitoba, CANADA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Moncton, New Brunswick, CANADA |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Ottawa, Ontario, CANADA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Toronto, Ontario, CANADA |
|
03/01/2008 |
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Nashville, TN USA |
|
03/01/2008 |
|
|
|
|
|
Details |
|
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
|
Kingston, Ontario, CANADA |
|
03/01/2008 |
|
|
|
Details |
|
Gliogene: Brain Tumor Linkage Study |
|
Tampa, FL USA |
|
01/17/2008 |
|
|
|
|
|
Details |
|
Gliogene: Brain Tumor Linkage Study |
|
Boston, MA USA |
|
01/17/2008 |
|
|
|
Details |
|
Gliogene: Brain Tumor Linkage Study |
|
San Francisco, CA USA |
|
01/17/2008 |
|
|
|
|
|
Details |
|
Gliogene: Brain Tumor Linkage Study |
|
New York, NY USA |
|
01/17/2008 |
|
|
|
Details |
|
Gliogene: Brain Tumor Linkage Study |
|
Houston, Tx USA |
|
01/17/2008 |
|
|
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
New York, NY USA |
|
08/26/2007 |
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
Cincinnati,, OH USA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
Columbus, OH USA |
|
08/26/2007 |
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
Toronto, Ontario, CANADA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme |
|
Winston-Salem, NC USA |
|
08/26/2007 |
|
|
|
Details |
|
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme |
|
Baltimore, MD USA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme |
|
Detroit, MI USA |
|
08/26/2007 |
|
|
|
Details |
|
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme |
|
Atlanta, GA USA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme |
|
Philadelphia, PA USA |
|
08/26/2007 |
|
|
|
Details |
|
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme |
|
Birmingham, AL USA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme |
|
Tampa, FL USA |
|
08/26/2007 |
|
|
|
Details |
|
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme |
|
Boston, MA USA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme |
|
Cleveland, OH USA |
|
08/26/2007 |
|
|
|
Details |
|
Determination of the In-Tumor-Concentration of Imatinib Mesylate (Gleevec) in Malignant Glioma After Oral Administration |
|
Baltimore, MD USA |
|
08/20/2007 |
|
|
|
|
|
Details |
|
A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas |
|
Vista, CA USA |
|
08/20/2007 |
|
|
|
Details |
|
A Phase II Trial With Cetuximab (Erbitux), Bevacizumab (Avastin) and Irinotecan (CPT-11) for Patients With Malignant Glioblastomas and Progression After Radiation Therapy and Temozolamide |
|
Copenhagen, Denmark |
|
08/20/2007 |
|
|
|
|
|
Details |
|
A Phase I Trial of Enzastaurin (LY317615) in Patients With Recurrent Gliomas |
|
Bethesda, MD USA |
|
08/20/2007 |
|
|
|
Details |
|
Eligibility Screening Of Patients With Central Nervous System Tumors For The National Cancer Institute`s (NCI) Clinical Research Protocols |
|
Bethesda, MD USA |
|
08/20/2007 |
|
|
|
|
|
Details |
|
A Phase II Trial of Bevacizumab (Avastin) and Irinotecan (CPT-11) for Patients With Recurrent High-Grade Gliomas Immediately Following Tumor Progression After Treatment With Bevacizumab Alone |
|
Bethesda, MD USA |
|
08/19/2007 |
|
|
|
Details |
|
Identification of factors associated with brain metastasis in women with breast cancer: development of a predictive nomogram |
|
Cleveland, OH USA |
|
08/18/2007 |
|
|
|
|
|
Details |
|
Identification of Hypermethylated Serum Tumor DNA in High Grade Glioma Patients and Correlation with Magnetic Resonance Imaging Findings |
|
Cleveland, OH USA |
|
08/18/2007 |
|
